Alzheimer's disease drug development and the problem of the blood‐brain barrier
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) drug development is limited by the presence of the blood‐brain barrier (BBB). More than 98% of all small‐molecule drugs, and ∼100% of all large‐molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present‐day AD drug‐development effort is characterized by an imbalance wherein >99% of the drug‐development effort is devoted to central nervous system (CNS) drug discovery, and <1% of drug development is devoted to CNS drug delivery. Future AD drug development needs a concerted effort to incorporate BBB sciences early in the CNS drug discovery process. This goal can be achieved by a reallocation of resources, and an expansion of research efforts in the pure science of BBB biology and the applied science of brain drug‐targeting technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“However, if affective disorders were excluded, only 1% of all drugs were active in the CNS [16].”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc9800071 · Cited by 3,068 · cited 1×
“7000 drugs in the Comprehensive Medicinal Chemistry database, only 5% of all drugs were effective in the CNS, and these drugs only treated a restricted number of brain disorders: depression, schizophrenia, and insomnia [15].”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Self-citationBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“10 mg/kg) of AAAs to nonimmunized AD mice resulted in the disaggregation of Ab amyloid plaque in brains behind the BBB [28,29].”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“Active immunization was ultimately terminated after findings of an encephalitislike clinical syndrome [27], which may have been caused by adjuvant-mediated BBB disruption.”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Jitsukawa, K., Sueki, H., Sato, S., & Anzai, T. (1987) · The American Journal of Dermatopathology · doi:10.1097/00000372-198704000-00003 · Cited by 1,131
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“The intracerebral administration of a retrovirus expressing BDNF is therapeutic in AD transgenic mice [42].”
BackgroundLang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983 · cited 1×
“The clinical trial was aborted owing to a lack of efficacy [7], and subsequent primate studies demonstrated poor penetration of the GDNF into the brain parenchyma with convection-enhanced diffusion [8].”
BackgroundCerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Selective expression of the large neutral amino acid transporter at the blood–brain barrier
Boado, R. J., Li, J. Y., Nagaya, M., Zhang, C., & Pardridge, W. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12079 · Cited by 481 · cited 1×
“The a-carboxylation of dopamine yields dihydroxyphenylalanine, which does cross the BBB via carrier-mediated transport on the large, neutral amino-acid transporter type 1, which is the protein product of the LAT1 gene [17].”
BackgroundSelf-citationA controlled trial of recombinant methionyl human BDNF in ALS
The BDNF Study Group (Phase III) (1999) · Neurology · doi:10.1212/wnl.52.7.1427 · Cited by 451
Disaggregation of Alzheimer β-amyloid by site-directed mAb
Solomon, B., Koppel, R., Frankel, D., & Hanan-Aharon, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 421 · cited 1×
“These results were in accord with other findings that the physical association of AAAs with amyloid plaque in vitro causes the disaggregation of Abeta amyloid [21].”
ResultWilcock, D. M., Rojiani, A. M., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., & Morgan, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-24 · Cited by 420
The movement of molecules across lipid membranes: A molecular theory
Träuble, H. (1971) · The Journal of Membrane Biology · doi:10.1007/bf02431971 · Cited by 391 · cited 1×
“Träuble [13] proposed a molecular model to explain the effect of molecular size on the membrane permeation of solutes.”
BackgroundBlood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion
Fischer, H., Gottschlich, R., & Seelig, A. (1998) · Journal of Membrane Biology · doi:10.1007/s002329900434 · Cited by 371 · cited 2×
“The BBB permeability decreases 100-fold when the surface area of a drug is increased from 50 Å(2) to 100 Å(2) [11], which would be the case when the MW of a drug is increased from 300 Da to 450 Da.”
BackgroundIntrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion.
Blasberg, R. G., Patlak, C., & Fenstermacher, J. D. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30311-3 · Cited by 343 · cited 1×
“Intra-cerebro-ventricular drug administration is not effective, because the drug only distributes to the ependymal surface of the brain [2,3].”
BackgroundPoint source concentration of GDNF may explain failure of phase II clinical trial
SALVATORE, M., AI, Y., FISCHER, B., ZHANG, A., GRONDIN, R., ZHANG, Z., GERHARDT, G., & GASH, D. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.015 · Cited by 260 · cited 1×
“The clinical trial was aborted owing to a lack of efficacy [7], and subsequent primate studies demonstrated poor penetration of the GDNF into the brain parenchyma with convection-enhanced diffusion [8].”
BackgroundFung, L. K., Shin, M., Tyler, B., Brem, H., & Saltzman, W. M. (1996) · Pharmaceutical Research · doi:10.1023/a:1016083113123 · Cited by 213 · cited 1×
“The intracerebral injection of a drug or polymeric implant is not effective, because the concentration of drug within the brain decreases exponentially from the injection site, and is only a fraction of its original concentration at distances ,1 mm from the depot site [5,6].”
BackgroundBoado, R. J., Zhang, Y., Zhang, Y., & Pardridge, W. M. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21120 · Cited by 203 · cited 1×
“The HIR MAb was genetically engineered, and both chimeric and humanized HIR MAbs rapidly cross the BBB in vivo in Old World primates such as the rhesus monkey [37].”
BackgroundSelf-citationRe-Engineering Biopharmaceuticals for Delivery to Brain with Molecular Trojan Horses
Pardridge, W. M. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800148t · Cited by 167 · cited 1×
“An alternative approach to the immune therapy of AD involves the re-engineering of AAAs to enable receptor-mediated transport (RMT) of the AAA across the BBB in both the blood-to-brain and brain-to-blood directions [35].”
BackgroundSelf-citationPlasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes.
Nadal, A., Fuentes, E., Pastor, J., & McNaughton, P. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1426 · Cited by 156 · cited 1×
“However, BBB disruption leads to the brain uptake of plasma proteins, and plasma albumin is toxic to astrocytes [25].”
BackgroundWilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., Ronan, V., Symmonds, K., Gordon, M. N., & Morgan, D. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0695-06.2006 · Cited by 153 · cited 1×
“A consistent side effect of passive immunization is BBB disruption and cerebral microhemorrhage [30,31]; The systemic administration of a therapeutic dose of an AAA results in an enormous increase in plasma concentration of the Ab peptide, from low nanomolar concentrations to nearly 1 mM [32]; and The marked elevation…”
BackgroundBrain Drug Targeting: The Future of Brain Drug Development
Pardridge, W. M. (2001) · Cited by 150
Self-citationAmyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations
Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149 · cited 1×
“The intracerebral injection of AAAs bypassed the BBB and allowed AAAs to physically interact with amyloid plaque, and this was associated with plaque disaggregation in vivo, and with the repair of dystrophic neurites [22].”
BackgroundBoado, R. J., Zhang, Y., Zhang, Y., Xia, C., Wang, Y., & Pardridge, W. M. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21602 · Cited by 142 · cited 1×
“Some HIR MAb fusion proteins were genetically engineered, whereby the neurotherapeutic protein, which does not cross the BBB, is fused to the carboxyl terminus of the heavy chain of the HIR MAb, and IgG fusion proteins were engineered for neurotrophins [38,39], enzymes [40,41], and single-chain Fv (ScFv) antibodies [3…”
BackgroundSelf-citationDiffusion of Small Non-Electrolytes across Liposome Membranes
COHEN, B. E., & Bangham, A. D. (1972) · Nature · doi:10.1038/236173a0 · Cited by 139 · cited 1×
“The MW threshold is a property of all biological membranes [10].”
Boado, R. J., Zhang, Y., Zhang, Y., Xia, C.-F., & Pardridge, W. M. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060349x · Cited by 133 · cited 11×
“Some HIR MAb fusion proteins were genetically engineered, whereby the neurotherapeutic protein, which does not cross the BBB, is fused to the carboxyl terminus of the heavy chain of the HIR MAb, and IgG fusion proteins were engineered for neurotrophins [38,39], enzymes [40,41], and single-chain Fv (ScFv) antibodies [3…”
InfluentialSelf-citationSakane, T., & Pardridge, W. M. (1997) · Pharmaceutical Research · doi:10.1023/a:1012117815460 · Cited by 126 · cited 1×
“The BDNF does not cross the BBB [43], which is why the clinical trials of amyotrophic lateral sclerosis with subcutaneous BDNF failed [44].”
BackgroundSelf-citationBrain Drug Targeting: The Future of Brain Drug Development
Pardridge, W. M. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511549571 · Cited by 118
Self-citationRabchevsky, A. G., Degos, J., & Dreyfus, P. A. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01479-1 · Cited by 116 · cited 1×
“The administration of Freund’s adjuvant to mice results in BBB disruption and leakage into the brain of circulating immunoglobulin G (IgG) molecules [23]; and”
BackgroundNon-stokesian nature of transverse diffusion within human red cell membranes
Lieb, W. R., & Stein, W. D. (1986) · The Journal of Membrane Biology · doi:10.1007/bf01870701 · Cited by 101 · cited 1×
“Lieb and Stein [12] noted that the diffusion of solutes through biological membranes is different from diffusion through water, and that a MW threshold existed for diffusion through membranes.”
BackgroundGDNF fusion protein for targeted‐drug delivery across the human blood–brain barrier
Boado, R. J., Zhang, Y., Zhang, Y., Wang, Y., & Pardridge, W. M. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21764 · Cited by 96 · cited 2×
“Neurotrophins, such as BDNF or GDNF, were re-engineered as HIR MAb-neurotrophin fusion proteins [38,39].”
BackgroundSelf-citationBoado, R. J., Zhang, Y., Zhang, Y., & Pardridge, W. M. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21369 · Cited by 87 · cited 2×
“Neurotrophins, such as BDNF or GDNF, were re-engineered as HIR MAb-neurotrophin fusion proteins [38,39].”
BackgroundSelf-citationIto, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85 · cited 1×
“With respect to Abeta efflux from brain, this may take place for Abeta monomers, but Aβ dimers do not efflux from brain [19].”
BackgroundStructural changes in the rat brain after carotid infusions of hyperosmolar solutions
Salahuddin, T. S., Johansson, B. B., Kalimo, H., & Olsson, Y. (1988) · Acta Neuropathologica · doi:10.1007/bf00688236 · Cited by 85 · cited 1×
“A single BBB disruption leads to chronic neuropathologic changes in the brain [26].”
BackgroundSaito, Y., Buciak, J., Yang, J., & Pardridge, W. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10227 · Cited by 81
Self-citationSu, G. C., Arendash, G. W., Kalaria, R. N., Bjugstad, K. B., & MULLAN, M. J. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01143-3 · Cited by 71 · cited 1×
“• The markedelevation of the plasma Aβ peptide concentration results in BBB disruption, non-specific IgG uptake by brain from blood, and cerebral microhemorrhage [33].”
Microdialysis study of zidovudine (AZT) transport in rat brain.
Dykstra, K. H., Arya, A., Arriola, D. M., Bungay, P. M., Morrison, P. F., & Dedrick, R. L. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39556-x · Cited by 70 · cited 1×
“The intracerebral injection of a drug or polymeric implant is not effective, because the concentration of drug within the brain decreases exponentially from the injection site, and is only a fraction of its original concentration at distances ,1 mm from the depot site [5,6].”
Backgroundβ-Amyloid (1–42) peptide impairs blood-brain barrier function after intracarotid infusion in rats
Jancsó, G., Domoki, F., Sántha, P., Varga, J., Fischer, J., Orosz, K., Penke, B., Becskei, A., Dux, M., & Tóth, L. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00622-3 · Cited by 68
Fate of adrenal cortical steroids following intrathecal injection
Fishman, K. A., & Christy, N. P. (1965) · Neurology · doi:10.1212/wnl.15.1.1 · Cited by 50 · cited 1×
“Drug injection into the CSF is similar to a slow intravenous injection, as noted by Fishman and Christy in 1965 [4].”
The non‐peptidyl fungal metabolite L‐783,281 activates TRK neurotrophin receptors
Wilkie, N., Wingrove, P. B., Bilsland, J. G., Young, L., Harper, S. J., Hefti, F., Ellis, S., & Pollack, S. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00504.x · Cited by 49 · cited 1×
“400 Da or high hydrogen bonding [45].”
Rishton, G. M., LaBonte, K., Williams, A. J., Kassam, K., & Kolovanov, E. A. (2006) · PubMed · Cited by 40
IgG-Paraoxonase-1 Fusion Protein for Targeted Drug Delivery across the Human Blood−Brain Barrier
Boado, R. J., Zhang, Y., Zhang, Y., Wang, Y., & Pardridge, W. M. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800113g · Cited by 31 · cited 1×
“Some HIR MAb fusion proteins were genetically engineered, whereby the neurotherapeutic protein, which does not cross the BBB, is fused to the carboxyl terminus of the heavy chain of the HIR MAb, and IgG fusion proteins were engineered for neurotrophins [38,39], enzymes [40,41], and single-chain Fv (ScFv) antibodies [3…”
BackgroundSelf-citationNamer, I. J., & Steibel, J. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00236-2 · Cited by 14 · cited 1×
“The intravenous administrationofanti-mannanantibodies results in the immediate disruption of the BBB [24].”
Background
Cited by
Xu, C., & Qu, X. (2014) · NPG Asia Materials · doi:10.1038/am.2013.88 · Cited by 1,133
The dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., Sharma, P., Siva Kumar, N., & Vekariya, R. L. (2020) · RSC Advances · doi:10.1039/d0ra03491f · Cited by 614
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases
Neef, D. W., Jaeger, A. M., & Thiele, D. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3453 · Cited by 307
Blood-brain barrier regulation in psychiatric disorders
Kealy, J., Greene, C., & Campbell, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.033 · Cited by 307
Metadata
- Authors
- Pardridge, W. M.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2009-09
- Volume
- 5
- Issue
- 5
- Pages
- 427-432
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2052766986
- Cited by
- 203
- References
- 47
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.